RAPT Therapeutics (RAPT) Gains from Sales and Divestitures: 2021-2024
Historic Gains from Sales and Divestitures for Therapeutics (RAPT) over the last 4 years, with Sep 2024 value amounting to $13,500.
- Therapeutics' Gains from Sales and Divestitures changed negligibly% to $13,500 in Q3 2024 from the same period last year, while for Sep 2024 it was $13,500, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $13,500 for FY2023, which is negligibly% changed negligibly from last year.
- According to the latest figures from Q3 2024, Therapeutics' Gains from Sales and Divestitures is $13,500, which was down 0.00% from $13,500 recorded in Q2 2024.
- Over the past 5 years, Therapeutics' Gains from Sales and Divestitures peaked at $14,125 during Q1 2021, and registered a low of $13,500 during Q1 2022.
- In the last 3 years, Therapeutics' Gains from Sales and Divestitures had a median value of $13,500 in 2024 and averaged $13,500.
- Data for Therapeutics' Gains from Sales and Divestitures shows a maximum YoY dropped of 4.42% (in 2022) over the last 5 years.
- Quarterly analysis of 4 years shows Therapeutics' Gains from Sales and Divestitures stood at $14,125 in 2021, then decreased by 4.42% to $13,500 in 2022, then remained steady at $13,500 in 2023, then remained steady at $13,500 in 2024.
- Its last three reported values are $13,500 in Q3 2024, $13,500 for Q2 2024, and $13,500 during Q1 2024.